Federal authorities have launched a criminal investigation into the practices at the company linked to a fungal meningitis outbreak blamed for 23 deaths, Massachusetts Gov. Deval Patrick told reporters Tuesday.
In addition, the Board of Registration in Pharmacy has voted to revoke permanently the New England Compounding Center's license to operate in Massachusetts as well as the licenses of the company's three principal pharmacists, Patrick said.
The announcements came in the wake of a damning nine-page report, released Tuesday by the board, which is part of the state's Department of Public Health.
Investigators for the state's DPH, working with their counterparts at the U.S. Food and Drug Administration, "identified serious deficiencies and significant violations of pharmacy law and regulations that clearly placed the public's health at risk," it said.
According to the investigator's preliminary findings, the Compounding Center:
-- Distributed large quantities of its products to facilities, "apparently for general use rather than requiring a prescription for an individual patient" as state law requires.
-- Distributed two recalled lots of methylprednisolone acetate before it had learned the results of sterility tests.
-- Did not follow proper sterilization standards.
-- Produced vials of methylprednisolone that were later recalled that contained "visible black particulate matter."
-- Failed to thoroughly clean powder hoods, which are intended to protect pharmacists from inhaling substances while medication is being prepared, which "may subsequently lead to contamination of compounded medications."
-- Used "visibly soiled" mats outside "clean rooms," potentially leading to their contamination.
-- Failed to repair a leaking boiler adjacent to the clean room, which resulted in a pool of water around the boiler and adjacent walls creating an unsanitary condition.
Patrick said the state would begin making unannounced inspections of pharmacies that prepare injectable medications and require that they submit annual reports detailing what they produce, how much of it and where it is distributed.
"It is now clear that the New England Compounding Center violated state law and endangered the health of countless patients," said U.S. Rep. Edward J. Markey, D-Massachusetts, in a statement.
The senior member of the Energy and Commerce Committee, which has jurisdiction over the FDA, vowed to introduce legislation to improve safety of drugs made by compounding pharmacies.
The incident began unfolding on September 24, when the department said it was notified about a cluster of six rare fungal meningitis cases in Tennessee. The patients shared several risk factors, including an epidural injection of a steroid -- methylprednisolone acetate 80 mg/ml preservative free -- that had been compounded at NECC in Framingham, Massachusetts.
The department soon learned that the suspect product had been distributed to more than 14,000 patients in 23 states.
Investigators arriving at the company on September 26 "found NECC employees cleaning sterile compounding areas and and conducting environmental testing," the report says. "DPH investigators also detected signs of bleach decontamination in the compounding areas."
DPH has asked two other companies -- Ameridose and Alaunus Pharmaceutical -- to cease all pharmacy operations based on their shared ownership and leadership with New England Compounding Center.
On October 15, federal authorities said that another NECC steroid injection, triamcinolone acetonide, might have caused a patient to acquire fungal meningitis, and they began contacting all 192 state facilities that received any NECC injectable products.